Evidence-based two-and-seven criteria according to tumor number and size best help to predict survival of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization

被引：0

作者：

Xia, D. ^{[1
]}

Bai, W. ^{[1
]}

Huang, M. ^{[2
]}

Sun, J. ^{[3
,4
]}

Wang, E. ^{[1
]}

Li, H. ^{[5
]}

Li, J. ^{[6
,17
]}

Zhao, H. ^{[7
]}

Pan, X. ^{[8
]}

Chen, S. ^{[9
]}

Gong, W. ^{[10
]}

Zhu, X. ^{[11
]}

Shao, G. ^{[12
]}

Mu, W. ^{[13
]}

Chen, Z. ^{[14
]}

Wu, J. ^{[15
]}

Liu, J. ^{[16
]}

Li, J. ^{[6
,17
]}

Song, J. ^{[18
]}

Zhang, C. ^{[19
]}

Shi, H. ^{[20
]}

Li, Z. ^{[21
]}

Yang, S. ^{[22
]}

Wang, W. ^{[1
,23
]}

Zheng, Y. ^{[24
]}

Xu, J. ^{[25
]}

Wang, W. ^{[1
,23
]}

Yuan, J. ^{[1
]}

Li, X. ^{[1
]}

Niu, J. ^{[1
]}

Yin, Z. ^{[1
]}

Fan, D. ^{[1
,26
]}

Xia, J. ^{[27
]}

Han, G. ^{[1
]}

机构：

[1] Forth Mil Med Univ, Xijing Hosp Digest Dis, Dept Liver Dis & Digest Intervent Radiol, Xian, Peoples R China

[2] Kunming Univ, Tumor Hosp Yunnan Prov, Affiliated Hosp 3, Dept Minimally Invas Int Therapy, Kunming, Peoples R China

[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary, Hangzhou, Zhejiang, Peoples R China

[4] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Pancreat Intervent Ctr, Hangzhou, Zhejiang, Peoples R China

[5] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Intervent Radiol, Zhengzhou, Peoples R China

[6] Third Mil Med Univ, Xinqiao Hosp, Dept Hepatobiliary Surg, Chongqing, Peoples R China

[7] Nantong Univ, Affiliated Hosp, Dept Intervent Radiol, Nantong, Peoples R China

[8] Peoples Liberat Army, Hosp 180, Clin Liver Dis Res Ctr, Quanzhou, Peoples R China

[9] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Prov Canc Hosp, Dept Intervent Radiol, Nanjing, Jiangsu, Peoples R China

[10] Forth Mil Med Univ, Dept Intervent Radiol, Tangdu Hosp, Xian, Peoples R China

[11] Soochow Univ, Dept Intervent Radiol, Affiliated Hosp 1, Suzhou, Peoples R China

[12] Zhejiang Prov Tumor Hosp, Dept Intervent Radiol, Hangzhou, Zhejiang, Peoples R China

[13] Third Mil Med Univ, Southwest Hosp, Dept Radiol, Chongqing, Peoples R China

[14] Fujian Med Univ, Affiliated Hosp 1, Dept Intervent Radiol, Fuzhou, Peoples R China

[15] Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China

[16] Hunan Prov Peoples Hosp, Dept Intervent Radiol & Vasc Surg, Changsha, Hunan, Peoples R China

[17] Sun Yat Sen Univ, Dept Intervent Radiol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China

[18] Shandong Prov Tumor Hosp, Dept Intervent Therapy, Jinan, Peoples R China

[19] Shandong Univ, Shandong Prov Hosp, Dept Gastroenterol & Hepatol, Jinan, Peoples R China

[20] Nanjing Med Univ, Dept Intervent Radiol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China

[21] Qingdao Univ, Affiliated Hosp, Intervent Med Ctr, Qingdao, Peoples R China

[22] Xinjiang Med Univ, Dept Intervent Radiol, Affiliated Tumor Hosp, Urumqi, Peoples R China

[23] Lanzhou Univ, Affiliated Hosp 1, Dept Intervent Med, Lanzhou, Peoples R China

[24] Yantai Yuhuangding Hosp, Dept Intervent Radiol, Yantai, Peoples R China

[25] Nanjing Mil Command, Nanjing Gen Hosp, Dept Med Imaging, Nanjing, Jiangsu, Peoples R China

[26] Fourth Mil Med Univ, Xijing Hosp Digest Dis, State Key Lab Canc Biol, Xian, Peoples R China

[27] Forth Mil Med Univ, Dept Hlth Stat, Xian, Peoples R China

来源：

JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期

关键词：

D O I：

10.1016/S0168-8278(17)30292-1

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

PS-020

引用

页码：S15 / S15

页数：1

共 40 条

[21] Survival and prognostic factors in patients with intermediate stage hepatocellular carcinoma (HCC) who were treated with repeated transarterial chemoembolization (TACE)
Kim, Jung hee
Jeong, Woo Kyoung
Sohn, Won
Paik, Yong-Han
Sinn, Dong Hyun
Gwak, Geum-Youn
Choi, Moon Seok
Lee, Joon Hyeok
Koh, Kwang Cheol
Paik, Seung Woon
HEPATOLOGY, 2015, 62 : 453A - 453A
[22] Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
Wang, Bi-Cheng
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
[23] Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models
Shim, Ju Hyun
Lee, Han Chu
Kim, Seon-Ok
Shin, Yong Moon
Kim, Kang Mo
Lim, Young-Suk
Suh, Dong Jin
RADIOLOGY, 2012, 262 (02) : 708 - 718
[24] Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate-stage hepatocellular carcinoma undergoing chemoembolization
Bannangkoon, Kittipitch
Hongsakul, Keerati
Tubtawee, Teeravut
CANCER IMAGING, 2023, 23 (01)
[25] FAIL-T (ALPHA-FETOPROTEIN, AST, TUMOR SIZE, ALT, AND TUMOR NUMBER): A MODEL TO PREDICT INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA PATIENTS WHO ARE NOT A GOOD CANDIDATE FOR TACE
Kaewdech, Apichat
Chamroonkul, Naichaya
Jandee, Sawangpong
Wetwittayakhlang, Panu
Piratvisuth, Teerha
Sripongpun, Pimsiri
GASTROENTEROLOGY, 2022, 162 (07) : S1157 - S1157
[26] Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers
Kimura, Haruki
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Sakakibara, Mitsuru
Imanaka, Kazuho
Tamura, Takeshi
Sueyoshi, Hironari
Takada, Ryoji
Fukutake, Nobuyasu
Uehara, Hiroyuki
Ashida, Reiko
Ioka, Tatsuya
Nakazawa, Tetsuro
Nakanishi, Katsuyuki
Katayama, Kazuhiro
HEPATOLOGY INTERNATIONAL, 2017, 11 (01) : 105 - 114
[27] Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers
Haruki Kimura
Kazuyoshi Ohkawa
Masanori Miyazaki
Mitsuru Sakakibara
Kazuho Imanaka
Takeshi Tamura
Hironari Sueyoshi
Ryoji Takada
Nobuyasu Fukutake
Hiroyuki Uehara
Reiko Ashida
Tatsuya Ioka
Tetsuro Nakazawa
Katsuyuki Nakanishi
Kazuhiro Katayama
Hepatology International, 2017, 11 : 105 - 114
[28] Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
Shimose, Shigeo
Kawaguchi, Takumi
Tanaka, Masatoshi
Iwamoto, Hideki
Miyazaki, Ken
Moriyama, Etsuko
Suzuki, Hiroyuki
Niizeki, Takashi
Shirono, Tomotake
Nakano, Masahito
Suga, Hideya
Yamaguchi, Taizo
Yokokura, Yoshinori
Noguchi, Kazunori
Koga, Hironori
Torimura, Takuji
ONCOLOGY LETTERS, 2020, 20 (03) : 2257 - 2265
[29] Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization
Chen, Hsin-Yeh
Kee, Kwong-Ming
Lu, Sheng-Nan
Wang, Jing-Houng
Chen, Chien-Hung
Hung, Chao-Hung
Yen, Yi-Hao
Kuo, Yuan-Hung
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (04) : 778 - 786
[30] A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization
Chang Liu
Lei Li
Wu-sheng Lu
Hua Du
Lu-nan Yan
Tian-fu Wen
Wu-ran Wei
Li Jiang
Ming-qing Xu
BMC Cancer, 18

← 1 2 3 4 →